Sponsors (22)
The bill strengthens infant formula safety and regulatory transparency through mandatory pathogen testing and rapid reporting, but increases compliance costs, risks supply disruptions, and pressures FDA to finalize rules quickly.
Infants and their caregivers: manufacturers must test facilities and finished formula for pathogens (including Clostridium botulinum) and notify FDA of positive results within one business day, improving early detection and the ability to prevent contaminated product reaching consumers.
Parents, families, and taxpayers: FDA must apply consistent inspection and compliance standards to all infant formula and provide committees of Congress timely written notice (within one business day) of positive tests or adverse inspection findings, increasing regulatory transparency and accountability.
Infant formula manufacturers, especially small and foreign producers: will incur higher compliance costs from added testing, recordkeeping, and faster reporting requirements, which may raise prices for families or reduce the number of suppliers in the market.
Parents, families, and health-care providers: immediate reporting of positive tests could trigger rapid recalls or supply disruptions before confirmatory testing or investigation, creating local or temporary shortages of formula.
Federal employees and consumers: the short (90-day) deadline for issuing final regulations could strain FDA resources and lead to rushed or unclear rules, undermining effective implementation and enforcement.
Based on analysis of 2 sections of legislative text.
Requires FDA to issue rules within 90 days mandating pathogen testing (including C. botulinum), one-business-day reporting of positives, records retention, and uniform inspection standards for infant formula.
Introduced March 9, 2026 by Rosa L. Delauro · Last progress March 9, 2026
Requires the FDA to issue rules within 90 days forcing infant formula manufacturers to run pathogen and environmental testing, report any positive finished-product tests to FDA within one business day, keep records of positives for inspection, and meet consistent inspection and compliance standards for all infant formula whether made in the U.S. or abroad. The agency must publish a list of pathogens to test (including Clostridium botulinum), set how often environmental testing must occur (including Zones 2 and 3), and notify designated congressional committees within one business day after receiving a positive finished-product test or after an inspection yields an “official action indicated” classification.